Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease

[1] Rascol O(2006)Development of dyskinesias in a 5-year trial of ropinirole and L-dopa Mov Disord 21 1844-1850

[2] Brooks DJ(2008)Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials Eur J Clin Pharmacol 64 1021-1026

[3] Korczyn AD(2004)Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1 Hum Mutat 23 540-545

[4] Arbouw ME(1997)A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia Hum Mol Genet 6 577-582

[5] Movig KL(2005)Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study Arch Neurol 62 601-605

[6] Guchelaar HJ(2002)A transmission disequilibrium test of the Ser9/Gly dopamine D3 receptor gene polymorphism in adult attention-deficit hyperactivity disorder Behav Brain Res 130 91-95

[7] Neville MJ(2006)A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor Proc Natl Acad Sci U S A 103 10753-10758

[8] Johnstone EC(2007)Pharmacogenetics of antiparkinsonian drug treatment: a systematic review Pharmacogenomics 8 159-176

[9] Walton RT(2005)Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease Mov Disord 20 1397-1404

[10] Arinami T(1996)Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system Biochem Biophys Res Commun 225 1068-1072

[1] Rascol O(2006)Development of dyskinesias in a 5-year trial of ropinirole and L-dopa Mov Disord 21 1844-1850

[2] Brooks DJ(2008)Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials Eur J Clin Pharmacol 64 1021-1026

[3] Korczyn AD(2004)Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1 Hum Mutat 23 540-545

[4] Arbouw ME(1997)A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia Hum Mol Genet 6 577-582

[5] Movig KL(2005)Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study Arch Neurol 62 601-605

[6] Guchelaar HJ(2002)A transmission disequilibrium test of the Ser9/Gly dopamine D3 receptor gene polymorphism in adult attention-deficit hyperactivity disorder Behav Brain Res 130 91-95

[7] Neville MJ(2006)A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor Proc Natl Acad Sci U S A 103 10753-10758

[8] Johnstone EC(2007)Pharmacogenetics of antiparkinsonian drug treatment: a systematic review Pharmacogenomics 8 159-176

[9] Walton RT(2005)Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease Mov Disord 20 1397-1404

[10] Arinami T(1996)Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system Biochem Biophys Res Commun 225 1068-1072